Skip to content

Evaluation of the Effect of Nasal Phenylephrine Drops in the Prevention of Hypotension Caused by Spinal Anesthesia in Patients Referred to the Operating Rooms

Evaluation of the Effect of Nasal Phenylephrine Drops in the Prevention of Hypotension Caused by Spinal Anesthesia in Patients Referred to the Operating Rooms

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240929063203N5
Enrollment
64
Registered
2026-03-14
Start date
2026-04-04
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Hypotension. Condition 2: Hypotension due to drugs. Hypotension Hypotension due to drugs

Interventions

Intervention 1: Intervention group: Candidates for cesarean section under spinal anesthesia received two drops of phenylephrine (0.5%) in each nostril
administration was performed 5 minutes before spinal anesthesia. Intervention 2: Control group: Patients received two drops of normal saline (physiological serum) in each nostril
administration was performed 5 minutes before spinal anesthesia.

Sponsors

Bandare-abbas University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Patients undergoing elective cesarean section surgery Patients aged 18 to 55 years ASA physical status class I-II Requirement for spinal anesthesia for elective cesarean section surgery

Exclusion criteria

Exclusion criteria: Allergy to phenylephrine Serious cardiovascular problems Hypertension Preeclampsia Patient refusal

Design outcomes

Primary

MeasureTime frame
Occurrence of hypotension (defined as a decrease of more than 20% in systolic blood pressure or systolic blood pressure less than 90 mmHg) following spinal anesthesia. Timepoint: From the time of spinal anesthesia injection until 30 minutes after injection. Method of measurement: Non-invasive measurement of blood pressure using vital signs monitor and recording in the patient's chart.;Need for additional vasopressors (such as etanephrine or ephedrine) to manage hypotension. Timepoint: From the time of spinal anesthesia injection until the end of surgery. Method of measurement: Recording the dose and frequency of vasopressor administration in the anesthesia record.;Occurrence of potential side effects caused by the use of phenylephrine drops (such as headache, nausea, bradycardia, or nasal congestion). Timepoint: From the time of drop instillation until 24 hours after surgery. Method of measurement: Patient questioning and clinical examination by the anesthesiologist.

Secondary

MeasureTime frame
Occurrence of nausea and vomiting during surgery or in recovery. Timepoint: From the start of surgery until discharge from the recovery room. Method of measurement: Clinical assessment and patient report; grading based on a standard scale (such as a 0 to 3 scale).;Occurrence of allergic reactions or nasal side effects caused by phenylephrine drops. Timepoint: Up to 24 hours after drop instillation. Method of measurement: Nasal examination and questioning the patient about symptoms such as burning, dryness, or runny nose.;Neonatal status in the first moments of life (Apgar score). Timepoint: At 1 minute and 5 minutes after birth. Method of measurement: Assessment by a pediatrician based on 5 standard criteria (heart rate, respiration, reflex, muscle tone, color).;Need for rescue treatments for hypotension (number of doses and total dose of ephedrine or other vasopressors). Timepoint: From anesthesia until the end of surgery. Method of measurement: Recording administered medications in the anesthesia record.;Patient satisfaction with the treatment method. Timepoint: In the recovery room or before discharge. Method of measurement: Questioning the patient using a questionnaire or Likert scale (e.g., from 1: Dissatisfied to 5: Completely satisfied).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBibimona Razavi

Bandare-abbas University of Medical Sciences

razavi.b.m.1@gmail.com0098 3334 5009

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026